论文部分内容阅读
1983年和1986年国家两次对中药价格管理办法进行改革。1986年,取消了对药材的国家定价,国家只对麝香、甘草、杜仲、厚朴4种药材规定指导性价格,其余品种放开。人参、牛黄等20种重点品种价格由中国药材公司每年组织一次全国性的协调。同时还调整了中药销售环节作价差率。这些措施,促进了中药事业的发展。近几年中药市场活跃,“抓药难”的问题已基本解决。但是,中药材价格改革后,由于配套管理措施没有跟上,忽视了必要的市场物价管理,以致多方插手,抬价抢购,层层加价,导致生产大上大下,市场混乱,
In 1983 and 1986, the state carried out two reforms to the management of Chinese medicine prices. In 1986, the country’s pricing for medicinal materials was cancelled. The state only provided directive prices for four kinds of medicinal materials, namely musk, licorice, eucommia, and honokiol, and other varieties were released. The prices of 20 key varieties such as ginseng and bezoar are coordinated by the Chinese Herbal Medicine Company once a year. At the same time also adjusted the sales cycle of Chinese medicine for the price difference. These measures have promoted the development of traditional Chinese medicine. In recent years, the traditional Chinese medicine market has been active and the problem of “difficulty in getting drugs” has been basically solved. However, after the reform of Chinese herbal medicine prices, due to the lack of supportive management measures, and ignoring the necessary management of market prices, many parties to intervene, rush to buy, and increase prices at all levels, resulting in a large production and market chaos.